GEN Exclusives

More »

GEN News Highlights

More »
Aug 4, 2010

NicOx to Shut Down U.S. Headquarters after Approval Setback for Osteoarthritis Drug

  • French firm NicOx is closing its U.S. headquarters effective August 31. The decision follows a review of the company’s structure and requirements after the FDA said it could not approve its lead candidate, naproxcinod. This CINOD (cyclooxygenase-inhibiting nitric oxide-donating) anti-inflammatory was developed for the relief of the signs and symptoms of osteoarthritis.

    NicOx shares slid 20%, reaching a 52-week low, on July 23, the day after it received FDA’s feedback. The agency asked that NicOx carry out additional long-term studies to evaluate naproxcinod’s cardiovascular and gastrointestinal risks. The company is also required to conduct trials to demonstrate that the therapeutic benefits of the drug are due to its nitric oxide-donating capabilities.

    NicOx plans to discuss possible next steps as early as possible with the FDA. The firm says that it will push on with the European regulatory process and is seeking partnerships for naproxcinod in Europe and the rest of the world. It is also looking to partner other products in its pipeline while pursuing in-licensing and M&A opportunities.

    The company reports that cash and cash equivalents as of June 30 were €128.4 million, and there is no long-term debt. NicOx is applying its nitric oxide-donating R&D platform to develop products for the potential treatment of inflammatory, cardio-metabolic, and ophthalmological diseases.

    The firm has a collaboration with Bausch & Lomb for the development and commercialization of NCX 116, a nitric oxide-donating prostaglandin F2-alpha analog. The firm has evaluated the compound as a treatment for primary open angle glaucoma or ocular hypertension. NicOx is also working with Merck & Co. to develop nitric oxide-donating antihypertensives and with Grupo Ferrer to develop nitric oxide-donationg anti-inflammatories for the treatment of skin disorders.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?